Riociguat · Adempas

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Pulmonary Arterial Hypertension

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
US
  • Chronic-Thromboembolic Pulmonary Hypertension Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class [see Clinical Studies (14.1) ].
Product first approved 2013FDA label
EU
  • CTEPH and pulmonary arterial hypertension (WHO FC II-III)
Product first approved 2014EMA
JP
  • Chronic thromboembolic pulmonary hypertension (CTEPH); PAH added in Feb 2015
Product first approved 2014clinicalleader.com
CA
  • Pulmonary Hypertension ADEMPAS (riociguat) is indicated for the treatment of:  inoperable chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4)  persistent or recurrent CTEPH after surgical treatment  pulmonary arterial hypertension (PAH, WHO Group 1), as monotherapy or in combination with endothelin receptor antagonists in adult patients (≥18 years of age) with WHO Functional Class II or III pulmonary hypertension. ADEMPAS should only be used by clinicians experienced in the diagnosis and treatment of CTEPH or PAH.
Product first approved 2013Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (9)
Pulmonary Arterial Hypertension
NCT02562235 · Bayer
2015-10-29 – 2028-05-15 · Hypertension, Pulmonary
What this study did
NCT04062565 · University of Arizona
2019-03-25 – 2025-12-31 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT07644377 · Assistance Publique - Hôpitaux de Paris
2026-11-01 – 2031-01-31 · CTEPH
What this study did
NCT05140525 · Dr Sudarshan Rajagopal
2025-01-27 – 2026-05-01 · CTEPH
What this study did
NCT00910429 · Bayer
2009-07-01 – 2019-08-19 · Pulmonary Hypertension
What this study did
NCT02007629 · Bayer
2014-02-18 – 2016-12-29 · Hypertension, Pulmonary
What this study did
NCT00855465 · Bayer
2009-02-23 – 2012-06-27 · Pulmonary Hypertension
What this study did
Phase 2 (21)
Pulmonary Arterial Hypertension
NCT05339087 · Heidelberg University
2022-10-24 – 2025-07-31 · Pulmonary Vascular Disorder, Primary Pulmonary Hypertension, Systemic Sclerosis, Other Systemic Involvement of Connective Tissue
What this study did
Other / comorbidity
NCT03409588 · University of Colorado, Denver
2018-06-13 – 2026-01-26 · Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
What this study did
NCT01065454 · Bayer
2010-04-14 – 2025-07-23 · Hypertension, Pulmonary, Ventricular Dysfunction, Left
What this study did
NCT04600492 · National Hospital Organization Okayama Medical Center
2020-10-16 – 2025-01-28 · Hypertension, Pulmonary
What this study did
NCT05762146 · Maastricht University
2022-09-05 – 2024-04-30 · Ischemic Stroke, Acute
What this study did
NCT02633397 · Mark Gladwin
2017-04-11 – 2022-05-04 · Sickle Cell Disease
What this study did
NCT02744339 · Medical University of Vienna
2016-03 – 2020-09 · Hypertension, Pulmonary, Heart Failure With Normal Ejection Fraction
What this study did
NCT03273257 · International CTEPH Association
2018-08-17 – 2020-05-05 · Chronic Thromboembolic Pulmonary Hypertension, CTEPH
What this study did
NCT02283762 · Bayer
2015-01-15 – 2019-03-28 · Scleroderma, Systemic
What this study did
NCT02915835 · Dinesh Khanna, MD, MS
2016-09 – 2018-07-24 · Scleroderma, Digital Ulcers
What this study did
NCT02170025 · Bayer
2014-09-30 – 2017-09-22 · Cystic Fibrosis
What this study did
NCT02138825 · Bayer
2014-06-04 – 2016-09-14 · Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
What this study did
NCT02094001 · Ottawa Heart Institute Research Corporation
2014-05 – 2016-06 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT00454558 · Bayer
2007-01 – 2014-09 · Hypertension, Pulmonary
What this study did
NCT01926847 · Bayer
2013-10 – 2014-06 · Raynaud Disease
What this study did
NCT01179334 · Bayer
2010-08 – 2013-05 · Pulmonary Hypertension
What this study did
NCT01165931 · Bayer
2012-05 – 2013-01 · Coronary Artery Disease
What this study did
NCT01172756 · Bayer
2010-07 – 2012-10 · Hypertension, Pulmonary, Ventricular Dysfunction, Left
What this study did
NCT01065051 · Bayer
2010-11 – 2011-01 · Hypertension, Pulmonary, Ventricular Dysfunction, Left
What this study did
Phase 1 (15)
Pulmonary Arterial Hypertension
NCT06180096 · Humanis Saglık Anonim Sirketi
2023-03-07 – 2023-04-06 · Pulmonary Arterial Hypertension
What this study did
Other / comorbidity
NCT04776499 · Maastricht University
2021-03-18 – 2022-02-28 · Drug Drug Interaction, Safety Issues
What this study did
NCT04211272 · Actelion
2020-01-14 – 2021-04-19 · Healthy
What this study did
NCT03389321 · Actelion
2018-01-09 – 2018-02-06 · Healthy Subjects
What this study did
NCT02556268 · Bayer
2016-02-23 – 2016-12-07 · HIV-DDI
What this study did
NCT02159326 · Bayer
2014-06 – 2015-07 · Drug Interactions
What this study did
NCT02159313 · Bayer
2014-06 – 2015-01 · Healthy Volunteers
What this study did
NCT01489488 · Bayer
2012-01 – 2012-05 · Pharmacology, Clinical
What this study did
NCT00855660 · Bayer
2009-03 – 2010-07 · Pharmacology, Clinical
What this study did
NCT01110590 · Bayer
2010-01 – 2010-05 · Erectile Dysfunction
What this study did
NCT00680654 · Bayer
2008-10 – 2009-11 · Hypertension, Pulmonary
What this study did
NCT00640315 · Bayer
2008-08 – 2009-09 · Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
What this study did
NCT00565565 · Bayer
2007-10 – 2009-04 · Heart Failure
What this study did
Phase 4 (9)
Pulmonary Arterial Hypertension
NCT05825417 · Sheffield Teaching Hospitals NHS Foundation Trust
2023-06-14 – 2028-01 · Pulmonary Arterial Hypertension
What this study did
NCT02759419 · Bayer
2016-06-16 – 2025-09-15 · Hypertension, Pulmonary
What this study did
NCT04954742 · Heidelberg University
2022-04-13 – 2025-08-13 · Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT03809156 · University of Calgary
2016-04-26 – 2021-01-31 · Pulmonary Hypertension
What this study did
NCT02891850 · Bayer
2017-01-11 – 2020-03-03 · Pulmonary Arterial Hypertension
What this study did
NCT02191137 · Bayer
2014-09-23 – 2016-07-16 · Hypertension, Pulmonary
What this study did
Other / comorbidity
NCT06715280 · Chinese University of Hong Kong
2024-07-25 – 2027-01-22 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
NCT02625558 · University of Cincinnati
2015-04 – 2018-10 · Sarcoidosis
What this study did
NCT02024386 · Richard Moon
2014-01 – 2015-12 · Hypertension, Pulmonary, Altitude Sickness
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT05750446 · Danish Headache Center
2023-06-01 – 2024-02-01 · Migraine Without Aura
What this study did
NCT05582811 · Danish Headache Center
2022-10-26 – 2023-06-01 · Headache
What this study did
NCT03074539 · Medical University of Vienna
2017-02-01 – 2022-12-31 · Chronic Thromboembolic Pulmonary Hypertension, Sleep Disordered Breathing
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT06922240 · Suqiao Yang
2025-03-21 – 2027-10-31 · Chronic Thromboembolic Pulmonary Hypertension
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT02634203 · Assistance Publique - Hôpitaux de Paris
2016-01-19 – 2020-01-27 · Chronic Thromboembolic Pulmonary Hypertension
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Pulmonary Arterial Hypertension: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Riociguat (Adempas): this drugApprovedSmall moleculeSoluble guanylate cyclaseReliable signal
NCT00810693: 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12 (Baseline and week 12): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT 29.6 Meters (Standard Deviation 65.8) | Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT 31.1 Meters (Standard Deviation 79.3) vs Placebo -5.6 Meters (Standard Deviation 85.5)
Ambrisentan (Letairis)ApprovedSmall moleculeEndothelin A receptorReliable signal
NCT01178073: Time to first adjudicated clinical failure: combination therapy vs pooled monotherapy, hazard ratio 0.502 (95% CI 0.348-0.724, p=0.0002) - 50% risk reduction
NCT00091598: 6-minute walk distance change from baseline to Week 12 (ARIES-1), placebo-corrected: +31 m with ambrisentan 5 mg (P=0.008); +51 m with ambrisentan 10 mg (P<0.001).
Bosentan (Tracleer)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00091715: Co-primary endpoints at month 6: pulmonary vascular resistance treatment effect -22.6% vs placebo (p<0.0001); 6-min walk distance (exercise capacity) treatment effect +19.1 m vs placebo (p=0.0758, not significant)
NCT00319267: AUCt for bosentan: geometric mean ratio of paediatric vs. historical-adult exposure = 0.54 (90% CI 0.37-0.78) — children had lower exposure than adults.
Epoprostenol (Flolan)
ApprovedUS marketing discontinued
Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Macitentan (Opsumit)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Partial signal
NCT00660179: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) (Up to end of treatment (data presented up to month 36)): ACT-064992 3 mg — Kaplan-Meier estimate at Month 6: 89.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 81.6 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 72.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 65.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 61.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 55 percentage of participants-Kaplan Meier | ACT-064992 10 mg — Kaplan-Meier estimate at Month 6: 92.7 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 85.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 79.9 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 74.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 70 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 63.2 percentage of participants-Kaplan Meier vs Placebo — Kaplan-Meier estimate at Month 6: 80.1 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 12: 71.4 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 18: 61.5 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 24: 57.3 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 30: 50.2 percentage of participants-Kaplan Meier; Kaplan-Meier estimate at Month 36: 47 percentage of participants-Kaplan Meier
Sildenafil (Revatio)ApprovedSmall moleculePDE5Partial signal
NCT00644605: The mean placebo-corrected treatment effects for 6-minute walk distance were 45 m (+13.0 percent), 46 m (+13.3 percent) and 50 m (+14.7 percent) for sildenafil doses of 20, 40 and 80 mg respectively; all comparisons achieved statistical significance (P<0.001).
Sotatercept (Winrevair)ApprovedProtein / enzyme therapeuticActivin receptor type IIA (ActRIIA)Reliable signal
NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5)
NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025).
Tadalafil (Adcirca)ApprovedSmall moleculePDE5Weak signal
NCT01824290: 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) missed
NCT00549302: 6-minute walk distance (6MWD), PHIRST-2 enrollment vs PHIRST-2 completion: tadalafil 20mg 406±67m (n=52) -> 415±80m (n=51); tadalafil 40mg 413±81m (n=59) -> 410±78m (n=59) - improvements from the 16-week PHIRST study were maintained through 52 additional weeks.
Treprostinil (Orenitram)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00325403: Six Minute Walk Distance (6MWD) (Baseline and Week 12): UT-15C (Oral Treprostinil) — 6MWD at Baseline: 350 meters (IQR 283 to 386); 6MWD at Week 12: 370 meters (IQR 300 to 418); Change in 6MWD from Baseline to Week 12: 25 meters (IQR -16 to 63) vs Placebo — 6MWD at Baseline: 339 meters (IQR 282 to 381); 6MWD at Week 12: 343 meters (IQR 246 to 403); Change in 6MWD from Baseline to Week 12: -5 meters (IQR -41 to 49)
Treprostinil (Remodulin)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso DPI)ApprovedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Treprostinil (Tyvaso)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT00147199: Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5)
Treprostinil (Yutrepia, Liquidia)ApprovedSmall moleculeIP receptor (prostacyclin pathway)Weak signalFeatured results are safety only in this race
Vericiguat (Verquvo)
Approved(overall)
Small moleculeSoluble guanylate cyclase
Reliable signal(overall)
No reviewed efficacy summary in this indication
Extended-Release Tacrolimus (VI-0106)Phase 3Small moleculeCalcineurinnot yet gradedNo reviewed efficacy summary in this indication
Imatinib Mesylate Prodrug (IkT-001Pro)Phase 3Small moleculePDGFR (imatinib-class)not yet gradedNo reviewed efficacy summary in this indication
Mosliciguat
Phase 3(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication
RalinepagPhase 3Small moleculeIP receptor (prostacyclin pathway)Reliable signal
NCT03626688: Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001.
SeralutinibPhase 3Small moleculePDGFR/CSF1R/KIT (multi-kinase)Partial signal
NCT05934526: Change in 6MWD at Week 24 (PROSERA): seralutinib +28.2m vs placebo +13.5m; Hodges-Lehmann placebo-adjusted treatment effect +13.3m (p=0.0320), which did not meet the prespecified α=0.025 significance threshold missed
Treprostinil (L606)Phase 3Small moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Udenafil (Zydena)Phase 2/3Small moleculePDE5Weak signalNo reviewed efficacy summary in this indication
APL-9796Phase 2Monoclonal antibodyZIP12 (zinc transporter)not yet gradedNo reviewed efficacy summary in this indication
Nurandociguat
Phase 2(overall)
Small moleculeSoluble guanylate cyclase
Partial signal(overall)
No reviewed efficacy summary in this indication
Praliciguat
Phase 2(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication
ROC-101Phase 2Small moleculeRho-associated kinase (ROCK, pan)not yet gradedNo reviewed efficacy summary in this indication
VasigrobartPhase 2Monoclonal antibodyPDGF-Bnot yet gradedNo reviewed efficacy summary in this indication
ZamicastatPhase 2Small moleculeDBHWeak signalNo reviewed efficacy summary in this indication
HS235Phase 1/2PeptideActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
SK-08
Phase 1(overall)
Small moleculeSoluble guanylate cyclase
not yet graded(overall)
No reviewed efficacy summary in this indication
F230
—(overall)
Small moleculeEndothelin A receptornot yet gradedNo reviewed efficacy summary in this indication
GSK6792070
—(overall)
UndisclosedActivin signallingnot yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)Weak signal
NCT01469169: Change in Pulmonary vascular resistance (PVR) from baseline to week 12: improved by -124 dyn·sec·cm-5 (95% CI, -177 to -72); 6-minute walking distance increased by 36.0 m (95% CI, 14.9 to 57.1)
PF-07868489DiscontinuedProtein / enzyme therapeuticBone morphogenetic protein 9 (BMP9)Partial signalNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Adempas (Riociguat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Phase 4Pulmonary Arterial HypertensionActive not recruiting
Est. primary completion 2028-01 · NCT05825417 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 3CTEPHNot yet recruiting
Est. primary completion 2031-01-31 · NCT07644377 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

August 2026ApprovalFDA updates Boxed Warning on Adempas (NDA204819)
US, FDA · FDA · Source ↗